
Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
Pharmaceutical companies must pay close attention to the safety of human subjects at every stage of drug development, as explained in this QA view of the policies and regulations that make the system work.
over 25 years ago
Letters to the Editorover 25 years ago
Conference Reportsover 25 years ago
Affairs of Stateover 25 years ago
Pen-Based Computingover 25 years ago
Some Do--Some Watch Over Those Who Doover 25 years ago
Communication Skills for Monitors—A Vital Training Opportunity





